InMed Pharmaceuticals (INM) announced the selection of an intravitreal, IVT, formulation for INM-089 as a drug candidate to be utilized in the Company’s ongoing development program targeting the treatment of dry age-related macular degeneration, AMD. InMed’s proprietary IVT formulation, combined with the INM-089 active pharmaceutical ingredient, has been successfully delivered to the targeted area of the eye in preclinical studies in doses of up to 10 times the calculated safety margin relative to the therapeutic dose level. This INM-089 IVT formulation will be used in the next stages of preclinical studies, including GLP-enabling studies and subsequent stages of clinical development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INM:
- Biotech Alert: Searches spiking for these stocks today
- InMed Pharmaceuticals Secures Key Patent for Cannabinoid Analogs
- InMed Pharmaceuticals granted an international PCT patent
- InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study
- InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study